[1]
Buenaventura Collazos, D., Aguilar Londoño, C., Aristizábal-Henao, N., Torres-Grajales, J. and Gutiérrez-Restrepo, J. 2025. Lenvatinib dose-escalation therapy in a patient with papillary thyroid carcinoma after discontinuation due to a severe adverse event . Revista Colombiana de Endocrinología, Diabetes & Metabolismo. 12, 2 (Jun. 2025). DOI:https://doi.org/10.53853/encr.12.2.934.